Loading...
•
Mar 31, 2020
Verrica Q1 2020 Earnings Report
Verrica reported a net loss for Q1 2020 and continued to advance VP-102 development.
Key Takeaways
Verrica Pharmaceuticals reported a net loss of $9.8 million for the first quarter of 2020, compared to a $7.5 million net loss for the same period in 2019. The company secured $55 million in non-dilutive loan facilities and continues to prepare for potential U.S. approval of VP-102.
Secured $55 million in non-dilutive loan facilities, with $35 million borrowed upon closing.
Received a patent in Japan for a cantharidin formulation.
Presented positive data on VP-102 at the Winter Clinical Dermatology Conference.
Prepares for potential U.S. approval of VP-102 for molluscum contagiosum
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...